Home » Kisoji, Cancer Research UK sign deal to advance KJ-103 into clinic

To read the full story, subscribe or sign in.

Immuno-oncology

Kisoji, Cancer Research UK sign deal to advance KJ-103 into clinic

Oct. 25, 2024

Cancer Research UK and Kisoji Biotechnology Inc. have signed an agreement to bring Kisoji's naked anti-TROP2 antibody, KJ-103, into a first-in-human trial. KJ-103 is a single domain antibody that binds to a unique epitope on TROP2.

BioWorld Science Collaboration Cancer Antibody Immuno-oncology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 31, 2025
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...
Novo weight-loss data roll out; Veru ‘leans’ in
BioWorld
As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line...
Appointments and advancements for Jan. 29, 2025
BioWorld
New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock.